TCR2 Therapeutics Inc. (TCRR)
| Market Cap | 1.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.50M |
| Shares Out | 30.34M |
| EPS (ttm) | -2.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $30.96 |
| Previous Close | $31.62 |
| Change ($) | -0.67 |
| Change (%) | -2.10% |
| Day's Open | 31.75 |
| Day's Range | 30.56 - 32.70 |
| Day's Volume | 1,381,253 |
| 52-Week Range | 6.01 - 34.07 |
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell ther...
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21
- TC-210 induced tumor regression in all of the first eight patients
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients s...
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suff...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suff...
- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell th...
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell th...
The company announced positive interim results for one of its experimental treatments.
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for ...
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for ...
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies fo...
About TCRR
TCR2 Therapeutics, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies... [Read more...]
| Industry Biotechnology | IPO Date Feb 14, 2019 |
| CEO Garry Menzel | Employees 109 |
| Stock Exchange NASDAQ | Ticker Symbol TCRR |
Analyst Forecasts
According to 9 analysts, the average rating for TCRR stock is "Strong Buy." The 12-month stock price forecast is 46.89, which is an increase of 51.48% from the latest price.